Logo image of ADVB

ADVANCED BIOMED INC (ADVB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ADVB - US00752P1049 - Common Stock

0.35 USD
-0.03 (-7.89%)
Last: 12/26/2025, 12:23:24 PM
Fundamental Rating

1

Overall ADVB gets a fundamental rating of 1 out of 10. We evaluated ADVB against 185 industry peers in the Health Care Equipment & Supplies industry. While ADVB seems to be doing ok healthwise, there are quite some concerns on its profitability. ADVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADVB has reported negative net income.
In the past year ADVB has reported a negative cash flow from operations.
ADVB Yearly Net Income VS EBIT VS OCF VS FCFADVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -1M -2M -3M -4M -5M

1.2 Ratios

Looking at the Return On Assets, with a value of -54.15%, ADVB is doing worse than 68.65% of the companies in the same industry.
ADVB has a Return On Equity of -112.52%. This is in the lower half of the industry: ADVB underperforms 63.78% of its industry peers.
Industry RankSector Rank
ROA -54.15%
ROE -112.52%
ROIC N/A
ROA(3y)-64.52%
ROA(5y)N/A
ROE(3y)-182.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADVB Yearly ROA, ROE, ROICADVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADVB Yearly Profit, Operating, Gross MarginsADVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

5

2. Health

2.1 Basic Checks

ADVB has about the same amout of shares outstanding than it did 1 year ago.
ADVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADVB Yearly Shares OutstandingADVB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M 20M
ADVB Yearly Total Debt VS Total AssetsADVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 2M 4M 6M

2.2 Solvency

ADVB has an Altman-Z score of -3.96. This is a bad value and indicates that ADVB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.96, ADVB is not doing good in the industry: 67.03% of the companies in the same industry are doing better.
ADVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACCN/A
ADVB Yearly LT Debt VS Equity VS FCFADVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 1.92 indicates that ADVB should not have too much problems paying its short term obligations.
The Current ratio of ADVB (1.92) is worse than 63.78% of its industry peers.
ADVB has a Quick Ratio of 1.92. This is a normal value and indicates that ADVB is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.92, ADVB perfoms like the industry average, outperforming 51.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
ADVB Yearly Current Assets VS Current LiabilitesADVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ADVB have decreased strongly by -23.48% in the last year.
EPS 1Y (TTM)-23.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADVB Price Earnings VS Forward Price EarningsADVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADVB Per share dataADVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADVB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ADVANCED BIOMED INC

NASDAQ:ADVB (12/26/2025, 12:23:24 PM)

0.35

-0.03 (-7.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-08 2025-10-08
Earnings (Next)04-13 2026-04-13
Inst Owners0.61%
Inst Owner Change100.06%
Ins Owners67.44%
Ins Owner ChangeN/A
Market Cap7.57M
Revenue(TTM)N/A
Net Income(TTM)-3.38M
AnalystsN/A
Price TargetN/A
Short Float %3.7%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.15%
ROE -112.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.52%
ROA(5y)N/A
ROE(3y)-182.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -3.96
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)28.65%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-166.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-173.95%
OCF growth 3YN/A
OCF growth 5YN/A

ADVANCED BIOMED INC / ADVB FAQ

Can you provide the ChartMill fundamental rating for ADVANCED BIOMED INC?

ChartMill assigns a fundamental rating of 1 / 10 to ADVB.


What is the valuation status of ADVANCED BIOMED INC (ADVB) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADVANCED BIOMED INC (ADVB). This can be considered as Overvalued.


Can you provide the profitability details for ADVANCED BIOMED INC?

ADVANCED BIOMED INC (ADVB) has a profitability rating of 0 / 10.


How financially healthy is ADVANCED BIOMED INC?

The financial health rating of ADVANCED BIOMED INC (ADVB) is 5 / 10.